hp0517020009.jpg hp0517020008.jpg
MANAGEMENT
ADVISORY BOARD
BUSINESS MODEL
FACILITIES
CAREERS
CONTACT US
ABOUT US
hp0517020007.jpg
TECHNOLOGY
LICENSING
LINKS

MEDICINE FOR THE WORLD'S WELL-BEING

R&D PROGRAMS
CANCER PROGRAM
DIABETES PROGRAM
RESEARCH & DEVELOPMENT
globe_animated2.gif
NEWS
March 2017 -


September 2015 -


September 2013 -


July 2011 -



October 2010 -




November 2009 -



August 2009 -



March 2008 -



October 2007 -
Housey Healthcare’s First Clinical Trial Approved in Canada!


HPRL Awarded two Phase I Small Business Innovation Research (SBIR) Grants for its on-going research programs.


Leading Merrill Lynch Financial Advisor, Frank Migliazzo, joins HPRL’s Advisory Board.


HPRL Awarded Phase II Continuation Small Business Innovation Research (SBIR) Grant for the "Discovery and Development of Anti-Diabetic Drugs" in Type I and Type II Diabetes.


HPRL Awarded Qualifying Therapeutic Discovery Tax Grants for two of its on-going research programs; "Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous Leukemia" and "Discovery and Development of Anti-Diabetic Drugs."


Dr. Charles Sawyers shares the 2009 Lasker Award for his work elucidating the mechanism of drug-resistance in Chronic Myelogenous Leukemia (CML).


HPRL Awarded Phase I Small Business Innovation Research (SBIR) Grant for "Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous Leukemia (CML)."


HPRL Awarded Phase II Small Business Innovation Research (SBIR) Grant for the "Discovery and Development of Anti-Diabetic Drugs."


The Juvenile Diabetes Research Foundation (JDRF) Partners with HPRL for therapeutic discovery and development in the area of Type I Diabetes.
®